- Home
- PAI vs ACRS Comparison
PAI vs ACRS Comparison
Compare PAI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAI
- ACRS
- Stock Information
- Founded
- PAI 1973
- ACRS 2012
- Country
- PAI United States
- ACRS United States
- Employees
- PAI N/A
- ACRS N/A
- Industry
- PAI Trusts Except Educational Religious and Charitable
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- PAI Finance
- ACRS Health Care
- Exchange
- PAI Nasdaq
- ACRS Nasdaq
- Market Cap
- PAI 118.3M
- ACRS 132.0M
- IPO Year
- PAI N/A
- ACRS 2015
- Fundamental
- Price
- PAI $12.33
- ACRS $2.55
- Analyst Decision
- PAI
- ACRS Strong Buy
- Analyst Count
- PAI 0
- ACRS 5
- Target Price
- PAI N/A
- ACRS $11.00
- AVG Volume (30 Days)
- PAI 25.0K
- ACRS 956.3K
- Earning Date
- PAI 01-01-0001
- ACRS 02-25-2025
- Dividend Yield
- PAI 4.78%
- ACRS N/A
- EPS Growth
- PAI N/A
- ACRS N/A
- EPS
- PAI N/A
- ACRS N/A
- Revenue
- PAI N/A
- ACRS $27,079,000.00
- Revenue This Year
- PAI N/A
- ACRS N/A
- Revenue Next Year
- PAI N/A
- ACRS N/A
- P/E Ratio
- PAI N/A
- ACRS N/A
- Revenue Growth
- PAI N/A
- ACRS 26.35
- 52 Week Low
- PAI $10.59
- ACRS $0.95
- 52 Week High
- PAI $12.63
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- PAI 46.08
- ACRS 44.33
- Support Level
- PAI $12.12
- ACRS $2.31
- Resistance Level
- PAI $12.51
- ACRS $2.64
- Average True Range (ATR)
- PAI 0.20
- ACRS 0.16
- MACD
- PAI 0.01
- ACRS 0.02
- Stochastic Oscillator
- PAI 26.19
- ACRS 58.76
About PAI Western Asset Investment Grade Income Fund Inc.
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed primarily as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.